Literature DB >> 356579

Natural history of myocardial infarction in the coronary drug project: long-term prognostic importance of serum lipid levels. Coronary Drug Project Research Group.

.   

Abstract

The relation between baseline fasting serum lipid levels (serum cholesterol and triglycerides) and 5 year rates for four end points--mortality from all causes, mortality from coronary heart disease, sudden death due to coronary heart disease and incidence of nonfatal myocardial infarction plus coronary death--was studied in 2,789 men. These were patients in the Coronary Drug Project placebo group who were 30 to 64 years old on entry and had recovered from one or more previous documented myocardial infarctions. Serum cholesterol was significantly related to all four end points, in both univariate and multivariate regression analyses (with control of 38 or 39 other factors in the latter). This significant relation of cholesterol to these end points was shown at low, medium and high levels of serum triglycerides. In contrast, baseline fasting serum triglyceride levels were not positively related to any of these end points. In these postmyocardial infarction patients, findings indicative of cardiovascular status at baseline evaluation, particularly the state of the myocardium, were more powerful prognosticators than serum cholesterol. These findings underscore the importance of efforts to prevent the first coronary episode. They also indicate the possibility after recovery from acute myocardial infarction of improving long-term prognosis through reduction of serum cholesterol.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 356579     DOI: 10.1016/0002-9149(78)90946-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  5 in total

Review 1.  Practical guidelines for drug therapy after myocardial infarction.

Authors:  L Wilhelmsen
Journal:  Drugs       Date:  1989-12       Impact factor: 9.546

2.  Apolipoprotein A and prognosis after myocardial infarction in non-diabetic men.

Authors:  H Pollak; O Arnoldner; W Enenkel; M Fischer; D Trubert-Exinger
Journal:  Klin Wochenschr       Date:  1991-01-04

Review 3.  Cholesterol in patients with coronary heart disease: how low should we go?

Authors:  H B Rubins
Journal:  J Gen Intern Med       Date:  1995-08       Impact factor: 5.128

4.  Should hyperhomocysteinemia be treated in patients with atherosclerotic disease?

Authors:  Bradley A Maron; Joseph Loscalzo
Journal:  Curr Atheroscler Rep       Date:  2007-11       Impact factor: 5.967

5.  All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.

Authors:  Raffaele De Caterina; Tanya Salvatore; Roberto Marchioli
Journal:  Data Brief       Date:  2016-04-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.